A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Phase 3 Terminated 68 enrolled Scynexis, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.

Timeline

Start: 2022-08-03
Primary completion: 2025-11-07
Completion: 2025-12-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Fluconazole	Small molecule	—	Oral
Subject	Ibrexafungerp	Small molecule	—	Oral
Background	Anidulafungin	Other / unclassified	—	Intravenous
Background	Caspofungin	Other / unclassified	—	Intravenous
Background	Micafungin	Peptide	—	Intravenous

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Summary

Timeline

Drugs

Indications